Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270821
Substrate
n/a
Meas. Tech.
ChEMBL_552585 (CHEMBL956457)
pH
6±n/a
Kd
170±n/a nM
Comments
extracted
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270821
Synonyms:
(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]acetamido}acetamido)-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid | CHEMBL446284
Type:
Small organic molecule
Emp. Form.:
C68H96N18O16S2
Mol. Mass.:
1485.731
SMILES:
CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:79.81,94.99,27.35,49.59,41.43,4.4,73.77,wD:60.63,16.24,45.47,98.102,(30.11,-18.61,;30.11,-20.15,;31.45,-20.92,;28.79,-20.92,;28.79,-22.47,;27.46,-23.23,;26.12,-22.47,;26.12,-20.92,;24.79,-23.23,;23.45,-22.47,;22.12,-23.24,;22.12,-24.78,;20.78,-22.47,;19.45,-23.25,;18.12,-22.47,;18.12,-20.93,;16.79,-23.24,;16.79,-24.78,;18.12,-25.55,;19.43,-24.78,;20.77,-25.55,;20.78,-27.09,;19.44,-27.86,;18.12,-27.1,;15.45,-22.48,;14.11,-23.24,;14.11,-24.78,;12.77,-22.47,;12.77,-20.93,;14.11,-20.16,;15.52,-20.79,;16.55,-19.64,;15.77,-18.31,;14.26,-18.63,;11.43,-23.23,;10.1,-22.47,;10.1,-20.92,;8.77,-23.24,;7.44,-22.46,;6.1,-23.23,;6.1,-24.77,;4.77,-22.46,;3.43,-23.23,;2.1,-22.46,;2.1,-20.92,;.77,-23.23,;-.57,-22.46,;-1.9,-23.24,;-1.9,-24.77,;-3.24,-22.47,;-3.24,-20.92,;-1.9,-20.16,;-.57,-20.94,;.76,-20.16,;.76,-18.61,;-.58,-17.85,;-1.9,-18.63,;-4.58,-23.23,;-5.93,-22.48,;-5.93,-20.94,;-7.26,-23.25,;-8.58,-22.46,;-7.26,-24.79,;-5.93,-25.56,;-5.93,-27.1,;-4.58,-27.85,;-4.6,-29.39,;-5.92,-30.14,;-3.27,-30.17,;.77,-24.77,;2.31,-24.77,;-.78,-24.76,;.77,-26.31,;4.77,-20.92,;3.44,-20.15,;6.1,-20.15,;30.11,-23.23,;30.11,-24.77,;31.45,-22.47,;32.78,-23.23,;34.12,-22.47,;34.12,-20.92,;32.79,-20.16,;32.79,-18.62,;34.12,-17.85,;34.12,-16.31,;35.45,-18.61,;35.47,-20.14,;32.78,-24.77,;31.45,-25.55,;34.12,-25.55,;35.69,-25.01,;36.72,-26.35,;35.76,-27.73,;34.36,-27.05,;33.03,-27.82,;31.7,-27.06,;33.03,-29.36,;31.7,-30.14,;30.38,-29.37,;29.04,-30.15,;31.7,-31.68,;30.37,-32.45,;33.04,-32.44,)|
Structure:
Search PDB for entries with ligand similarity: